Diabetes Care, Vol 17, Issue 10 1100-1109, Copyright © 1994 by American Diabetes Association

ARTICLES

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study

LS Hermann, B Schersten, PO Bitzen, T Kjellstrom, F Lindgarde and A Melander
Department of Community Health Sciences, Lund University, Dalby, Sweden.

OBJECTIVE--To assess and compare the therapeutic efficacy and safety of metformin (M) and sulfonylurea (glyburide, G), alone and in various combinations, in patients with non-insulin-dependent diabetes mellitus (NIDDM). RESEARCH DESIGN AND METHODS--Of 165 patients (fasting blood glucose [FBG] > or = 6.7 mmol/l) initially treated with diet alone, 144 (FBG still > or = 6.7 mmol/l) were randomized to double-blind, double-dummy controlled treatment with M, G, or primary combination therapy (MG). The dose was titrated, with FBG < 6.7 mmol/l as target, using, at most, six dose levels. The first three dose levels comprised increasing single-drug therapy (M or G) or primary combination at increasing but low dosage (MGL), and the second three levels were composed of various high-dose combinations, i.e., add-on therapy (M/G or G/M) and primary combination escalated to high dosage (MGH). Medication was maintained for 6 months after completed dose titration. RESULTS--The FBG target was achieved in 9% of patients after diet alone. Single-drug therapy was insufficient in 36% and MGL in 25% (NS) of the randomized patients. There was further improvement in glucose control by the high-dose combinations. Mean FBG +/- SE was reduced (P = 0.001) from 9.1 +/- 0.4 to 7.0 +/- 0.2 mmol/l in those maintained on single-drug treatment or low-dose primary combination. Those treated with different high-dose combinations had a large mean FBG reduction, from 13.3 +/- 0.8 to 7.8 +/- 0.6 mmol/l. HbA1c levels showed corresponding reductions, and glycemic levels rose after drug discontinuation. Fasting C-peptide rose during treatment with G and MGL but not with M, while fasting insulin was not significantly changed. Meal-stimulated C-peptide and insulin levels were unchanged by M but increased by G and, to a lesser extent, by MGL. There were no significant insulin or C-peptide differences between the different high-dose combinations (M/G, G/M, and MGH). Body weight did not change following treatment with M or combination but increased by 2.8 +/- 0.7 kg following G alone. Blood pressure was unchanged. Overall effects on plasma lipids were small, with no significant differences between groups. Drug safety was satisfactory, even if the reporting of (usually modest) adverse events was high; the profile, but not the frequency, differed between groups. CONCLUSIONS--Dose-effect titrated treatment with either metformin or glyburide promotes equal degrees of glycemic control. The former, but not the latter, is able to achieve this control without increasing body weight or hyperinsulinemia. Near-normal glycemia can be obtained by a combination of metformin and sulfonylurea, even in advanced NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Selvin, S. Bolen, H.-C. Yeh, C. Wiley, L. M. Wilson, S. S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E. B. Bass, et al. Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review Arch Intern Med, October 27, 2008; 168(19): 2070 - 2080. [Abstract] [Full Text] [PDF]

				E. R. Pearson, L. A. Donnelly, C. Kimber, A. Whitley, A. S.F. Doney, M. I. McCarthy, A. T. Hattersley, A. D. Morris, and C. N.A. Palmer Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas: A GoDARTs Study Diabetes, August 1, 2007; 56(8): 2178 - 2182. [Abstract] [Full Text] [PDF]

				T. L. Skaer, D. A. Sclar, and L. M. Robison Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001: Does Type of Insurance Influence Access to Innovation? The Diabetes Educator, November 1, 2006; 32(6): 940 - 953. [Abstract] [Full Text] [PDF]

				C. Triplitt, L. Glass, Y. Miyazaki, E. Wajcberg, A. Gastaldelli, E. De Filippis, E. Cersosimo, and R. A. DeFronzo Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care, November 1, 2006; 29(11): 2371 - 2377. [Abstract] [Full Text] [PDF]

				S. Schwartz, V. Fonseca, B. Berner, M. Cramer, Y.-K. Chiang, and A. Lewin Efficacy, Tolerability, and Safety of a Novel Once-Daily Extended-Release Metformin in Patients With Type 2 Diabetes Diabetes Care, April 1, 2006; 29(4): 759 - 764. [Abstract] [Full Text] [PDF]

				B. Schultes, A. Peters, M. Hallschmid, C. Benedict, V. Merl, K. M. Oltmanns, J. Born, H. L. Fehm, and W. Kern Modulation of Food Intake by Glucose in Patients With Type 2 Diabetes Diabetes Care, December 1, 2005; 28(12): 2884 - 2889. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				F. A. Masoudi, S. E. Inzucchi, Y. Wang, E. P. Havranek, J. M. Foody, and H. M. Krumholz Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study Circulation, February 8, 2005; 111(5): 583 - 590. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				B. Schultes, K. M. Oltmanns, W. Kern, H. L. Fehm, J. Born, and A. Peters Modulation of Hunger by Plasma Glucose and Metformin J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1133 - 1141. [Abstract] [Full Text] [PDF]

				P. Phillips, J. Karrasch, R. Scott, D. Wilson, and R. Moses Acarbose Improves Glycemic Control in Overweight Type 2 Diabetic Patients Insufficiently Treated With Metformin Diabetes Care, February 1, 2003; 26(2): 269 - 273. [Abstract] [Full Text] [PDF]

				R. K. Campbell and J. White Counseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient Setting The Diabetes Educator, November 1, 2002; 28(6): 938 - 957. [PDF]

				D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers Metformin: An Update Ann Intern Med, July 2, 2002; 137(1): 25 - 33. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				E. S. Holmboe Oral Antihyperglycemic Therapy for Type 2 Diabetes: Clinical Applications JAMA, January 16, 2002; 287(3): 373 - 376. [Abstract] [Full Text] [PDF]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]

				J. D. Peuler Opposing adrenergic actions of intravenous metformin on arterial pressure in female spontaneously hypertensive rats Cardiovasc Res, July 1, 1999; 43(1): 237 - 247. [Abstract] [Full Text] [PDF]

				M. S. Muntzel, I. Hamidou, and S. Barrett Metformin Attenuates Salt-Induced Hypertension in Spontaneously Hypertensive Rats Hypertension, May 1, 1999; 33(5): 1135 - 1140. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi, D. G. Maggs, G. R. Spollett, S. L. Page, F. S. Rife, V. Walton, and G. I. Shulman Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus N. Engl. J. Med., March 26, 1998; 338(13): 867 - 873. [Abstract] [Full Text] [PDF]

				A. L. Rosenbloom, D. V. House, and W. E. Winter Non-Insulin Dependent Diabetes Mellitus (NIDDM) in Minority Youth: Research Priorities and Needs Clinical Pediatrics, February 1, 1998; 37(2): 143 - 152. [Abstract] [PDF]

				M. S. Muntzel, A. Abe, and J. S. Petersen Effects of Adrenergic, Cholinergic and Ganglionic Blockade on Acute Depressor Responses to Metformin in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 618 - 623. [Abstract] [Full Text]

				J. S. Petersen, W. Liu, D. R. Kapusta, and K. J. Varner Metformin Inhibits Ganglionic Neurotransmission in Renal Nerves Hypertension, May 1, 1997; 29(5): 1173 - 1177. [Abstract] [Full Text]

				J. S. Petersen and G. F. DiBona Acute Sympathoinhibitory Actions of Metformin in Spontaneously Hypertensive Rats Hypertension, March 1, 1996; 27(3): 619 - 625. [Abstract] [Full Text]

				C. J. Bailey and R. C. Turner Metformin N. Engl. J. Med., February 29, 1996; 334(9): 574 - 579. [Full Text] [PDF]

				R. R. Henry and S. Genuth Forum One: Current Recommendations about Intensification of Metabolic Control in Non-Insulin-dependent Diabetes Mellitus Ann Intern Med, January 1, 1996; 124(1_Part_2): 175 - 177. [Abstract] [Full Text]

				B. Saulie, J. White, and R. K. Campbell Pharmacy Update: Metformin in the Treatment of Non-Insulin-Dependent Diabetes Mellitus The Diabetes Educator, January 1, 1995; 21(5): 441 - 445. [PDF]

				J. J. Tanja Jon J. Tanja, RPh, Ms, Fascp; Theresa M. Langlass, RPh, PharmD The Diabetes Educator, January 1, 1995; 21(6): 509 - 514. [PDF]